ERBB2 and extramammary Paget disease: Studies suggest that EMPD patients with low Erb-B2 receptor tyrosine kinase 2 (ERBB2) (HER2) expression exhibit heightened immunogenicity and enriched immune pathways, making them prime candidates for B-cell-related immunotherapy [65].